Renaissance Capital logo

Kite Pharma

Priced, Nasdaq: KITE

Biotech developing cancer immunotherapies with the National Cancer Institute.

Industry: Health Care

First Day Return: +70.6%

Biotech developing cancer immunotherapies with the National Cancer Institute.
IPO Data
IPO Date 06/19/2014
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $128
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Santa Monica, CA, United States
Founded 2009
Employees at IPO 19
Website www.kitepharma.com

Kite Pharma (KITE) Performance